Latest Peptide News
Original reporting on the peptide industry — FDA actions and compounding decisions, supply and shortage changes, new clinical trial results, and peer-reviewed research on the peptides people actually track. Published every other day, sourced to primary documents, and written for people managing a protocol rather than for clinicians.
Browse by peptide
Peptide News
GLP-1 Non-Responders: New SELECT Analyses and a Nature Report on Why Response Varies
A Nature news feature published this week puts a spotlight on GLP-1 non-responders — the people who take semaglutide or tirzepatide and see little weight change — while two fresh analyses of the SELECT trial dig into who loses the most and whether weight loss is what drives the drugs' cardiovascular benefit. For anyone tracking a GLP-1 protocol, the research reframes what a plateau actually means.
GLP-1 Muscle Loss Study Will Track DXA Scans and Grip Strength
An observational GLP-1 muscle loss study posted to ClinicalTrials.gov on September 22 will measure body composition with DXA scans plus physical function tests in adults already starting GLP-1 receptor agonist therapy. It lands alongside a new review in Maturitas that flags muscle health as one of the open questions for semaglutide in postmenopausal women.
Tirzepatide Abdominal Fat Study From SURMOUNT-J Hits PubMed
A tirzepatide abdominal fat study drawn from the SURMOUNT-J trial has been indexed in PubMed, reporting changes in abdominal adiposity and their associations with metabolic health markers in Japanese participants with obesity disease. It lands alongside two newly posted registry records comparing weekly incretin drugs head to head.
Tirzepatide Eye Side Effects Reported in New Stye Case Series
A newly indexed case series in JCEM Case Reports documents simultaneous and recurrent eyelid styes and chalazia in people taking tirzepatide, putting a rarely discussed category of tirzepatide eye side effects into the published literature. The report is small and observational, but it arrives alongside several other new case-level safety papers across the GLP-1 class.
Tirzepatide Muscle Loss Trial Tests Resistance Training in 150 Adults
A newly listed tirzepatide muscle loss trial in Germany will measure contractile thigh muscle volume in 150 adults on the dual GIP/GLP-1 agonist, randomising them to resistance training or standard care. It lands alongside two new journal reviews on nutrient intake and nutritional deficiencies during GLP-1 therapy, and together they mark how quickly lean mass and nutrition have moved to the centre of incretin research.
Cagrilintide Retatrutide Combination Boosts Weight Loss in Rat Study
A team publishing in Nature Metabolism reports that a cagrilintide retatrutide combination enhanced weight loss and metabolic outcomes in obese male rats, adding rodent evidence to the idea that amylin analogues and incretin agonists work better together. The finding lands while retatrutide itself is still investigational and, separately, while antidoping chemists publish methods for detecting it in human plasma and urine.
Tirzepatide Shortage Resolved, FDA Says, With New Compounder Guidance
The US Food and Drug Administration has declared the tirzepatide shortage resolved and issued clarified policies for compounders as national GLP-1 supply stabilizes. Because compounding copies of a commercially available drug is generally permitted only while that drug is in shortage, the determination reaches directly into how many people currently obtain their medication.
GLP-1 After Bariatric Surgery: Phase 4 Trial Now Recruiting
Two academic randomized trials are now attacking the same unanswered question: what should happen to GLP-1 after bariatric surgery. One is recruiting 150 patients in Missouri; the other, GRABS, has just published its rationale, design and baseline characteristics. For anyone tracking a GLP-1 protocol through a planned surgery, this is the evidence that does not yet exist.
NNC0662-0419 Phase 2 Trial Compares Novo Drug to Semaglutide
A newly posted NNC0662-0419 phase 2 trial record shows Novo Nordisk testing an experimental blood-sugar medicine head-to-head against semaglutide in 270 people with type 2 diabetes. For anyone following what comes after the current generation of GLP-1 drugs, the choice of comparator is the detail worth noting.
Cagrilintide Bone Density Trial Opens With Semaglutide Comparator
A newly posted cagrilintide bone density trial puts an amylin analogue head-to-head with semaglutide and with the CagriSema combination, and its stated purpose is bone health rather than weight. For anyone tracking a GLP-1 or incretin protocol, it is a signal that skeletal outcomes are moving from footnote to primary question.
Tirzepatide Binge Eating Disorder Trial Opens at Johns Hopkins
A Phase 2 tirzepatide binge eating disorder trial run by Johns Hopkins University is listed as recruiting on ClinicalTrials.gov, with 105 planned participants and a three-arm design that pits the dual incretin drug against both placebo and an established binge-eating medication. It is one of the first registered attempts to test whether an incretin therapy does anything for binge eating that is separable from weight loss.
Semaglutide Smoking Cessation Trial Opens Recruiting in Diabetes
A new semaglutide smoking cessation trial listed on ClinicalTrials.gov is recruiting 100 participants with diabetes to test the GLP-1 receptor agonist as an add-on to nicotine replacement therapy. It is one of several studies registered or published this week pushing incretin drugs well beyond weight and glucose control.